| Autor: |
Tauseef, Abubakar, Zafar, Maryam, Silberstein, Peter, Nahas, Joseph, Frederickson, Thomas, Hansen, Sean, Abbas, Anum, Alali, Yaman, Buragadda, Avdesh, Abughanimeh, Omar K., Nair, Sunil, Thirumalareddy, Joseph, Mirza, Mohsin |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Fed Pract |
| ISSN: |
1078-4497 |
| Popis: |
BACKGROUND: Despite the use of platinum-based chemotherapy, lung cancer continues to be the leading cause of cancer-related death in the world. To overcome the rate of lung cancer–related death, scientists discovered advanced therapies, including mutant epidermal growth factor receptor–tyrosine kinase (EGFR-TK) inhibitors. OBSERVATIONS: We conducted a meta-analysis to determine the safety profile of mutant EGFR-TK inhibitors in the management of advanced non–small cell lung cancer (NSCLC). Included in this study are 9 phase 3 randomized controlled trials designed to study the safety profile of mutant EGFR-TK inhibitors in patients with advanced NSCLC. The study showed that mutant EGFR-TK inhibitors have an incidence of adverse effects that is less reported when compared with platinum-based chemotherapy. CONCLUSIONS: We recommend continuing using mutant EGFR-TK inhibitors in patients with advanced NSCLC especially in patients having mutant EGFR receptors. Adverse effects caused by mutant EGFR-TK inhibitors are significant but are usually tolerable and can be avoided by reducing the dosage of it with each cycle or by skipping or delaying the dose until patient is symptomatic. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
